Core Biogenesis, a Strasbourg, France-based biotechnology company with a novel plant-based bioproduction platform, completed a $10.5M Series A funding round.
The round was led by XAnge, with participation from Blue Horizon Ventures, and Thia Ventures.
The company intends to use the funds to build out an industrial scale facility dedicated to producing growth factors and cytokines for the cell therapy market and cellular agriculture industry, and to hire additional scientific and technical staff to support the expansion.
Founded in May 2020 by CEO Alexandre Reeber and CSO Chouaib Meziadi, Core Biogenesis has developed proprietary technology to express recombinant proteins from the seeds of the Camelina sativa oilseed plant. While its molecular farming platform can be used to express recombinant growth factors for everything from therapeutics to cultivated meat, the company’s first target is to address the complexity and high costs of next-generation therapeutic modalities such as cell therapies.
As the company builds out the new manufacturing facility, they are also growing their team of scientific and technical experts to a total of 30 employees, with plans for additional expansions in the future.
FinSMEs
29/07/2022